Interpretation of management guidelines for preventing exposure to antineoplastics
Liu Wei, Wu Ziyang, Du Guanhua, Li Baohua, Miao Liyan, Song Haiqing, Wang Yuqin, Yang Kehu, Zhang Xianglin, Zhang Yanhua, Zhang Yu, Zhu Zhu, Zhu Jun, Zhai Suodi
Abstract
Exposure to antineoplastics is a potential health threat. If improperly disposed, it will also cause environmental pollution, which is a medical safety issue worthy of attention. In order to improve the protection awareness of healthcare professionals exposed to antineoplastic drugs (medical personnels, drug transportation staffs, patients and their caregivers, etc.), standardize exposure protection operations, and reduce the risk and harm of occupational exposure, the Division of Therapeutic Drug Monitoring of Chinese Pharmacological Society, the Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association, the Oncology Society of Chinese Medical Association, the Nursing Branch of China International Exchange and Promotive Association for Medical and Healthcare, and Chinese Pharmacological Society Professional Committee of Drug-induced Diseases formulated the Management guidelines for preventing exposure to antineoplastics, which was published in the 1st issue of Chinese Journal of Cancer Research in 2023. The guideline was developed referring to the World Health Organization handbook for guideline development and other international methodologies and focused on the full-process management of antineoplastics in hospitals. Using the Delphi method, clinical questions and 14 recommendations were formulated. This paper interprets 14 recommendations, hoping to help promote the implementation of the guideline.
Key words:
Antineoplastics; Exposure prevention; Guideline; Interpretation
Contributor Information
Liu Wei
Department of Pharmacy, Peking University Third Hospital, Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China
Wu Ziyang
Department of Pharmacy, Peking University Third Hospital, Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China
Du Guanhua
Institute of Materia Medica, Chinese Academy of Medical Science &
Peking Union Medical College, Beijing 100191, China
Li Baohua
Nursing Department, Peking University Third Hospital, Beijing 100191, China
Miao Liyan
Department of Pharmacy, First Affiliated Hospital of Soochow University, Zhejiang Province, Soochow 215006, China
Song Haiqing
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
Wang Yuqin
Department of Pharmacy, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
Yang Kehu
Evidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China
Zhang Xianglin
Department of Pharmacy, China-Japan Friendship Hospital, Beijing 100029, China
Zhang Yanhua
Department of Pharmacy, Peking University Cancer Hospital &
Institute, Beijing 100142, China
Zhang Yu
Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
Zhu Zhu
Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China
Zhu Jun
Department of Lymphoma, Peking University Cancer Hospital &
Institute, Beijing 100142, China
Zhai Suodi
Department of Pharmacy, Peking University Third Hospital, Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China
